Calendario›IONS›Alicaforsen

Alicaforsen

ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis

Ensayo de IONIS PHARMACEUTICALS INC en Colitis ulcerosa.

Más ensayos de: Colitis ulcerosa.

Fase

Fase 2

Estado

Completado

Centros

1

Fin del objetivo primario

mar 2005

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención. Comenzó en nov 2002.

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a multi-center trial to test the safety, efficacy and tolerability of alicaforsen (ISIS 2302), a new type of drug called an antisense drug, in patients with mild to moderate active Ulcerative Colitis (UC). Alicaforsen is designed to reduce the production of a specific protein, called ICAM-1, a substance that plays a significant role in the increase of inflammation and is likely to be involved in inflammatory bowel diseases such as ulcerative colitis. The ISIS 2302-CS22 study will examine the effects of one of two dosages of alicaforsen delivered by enema over a six-week period as compared to an active control, mesalamine enema (The probability of receiving the alicaforsen formulation is 2:1). The primary objective of this study is to evaluate the percentage reduction in DAI at Week 6.

Más ensayos de IONS

Todos los de IONS, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT00063414), actualizada en dic 2022.